Abstract
Severe asthma is a complex and heterogeneous phenotype characterized by persistent symptoms and poor control. While some patients respond to high doses of inhaled corticosteroids in combination with long-acting beta-agonists, a significant subset require oral corticosteroids to achieve symptom control. This issue has led to the development of alternative therapeutic strategies for severe asthma. This article provides an overview of current therapeutic strategies and suggests how they can be best applied to the treatment of severe asthma. The article then reviews alternative therapeutic strategies including macrolide antibiotics, biologic agents, modulators of signal transduction pathways and bronchial thermoplasty. The challenge remains to determine the appropriate phenotype for each therapeutic strategy in view of the heterogeneity of severe asthma.
Keywords: Severe asthma, new asthma therapy, corticosteriods, macrolides, biologic agents, neutrophilic, beta2, obliterans, emphysema, pulmonary edema, eosinophilic pneumonia, ABPA, Churg-Strauss syndrome, benign, malignant tumors, co-morbidities, cigarette smoking, anti-inflammatory therapy, synergistically
Current Pharmaceutical Design
Title: Challenges in the Management of Severe Asthma: Role of Current and Future Therapies
Volume: 17 Issue: 7
Author(s): Ron Oliveinstein, Hamdan Al Jahdali, Nouf Alkhamis, Rabih Halwani, Saleh Al-Muhsen and Qutayba Hamid
Affiliation:
Keywords: Severe asthma, new asthma therapy, corticosteriods, macrolides, biologic agents, neutrophilic, beta2, obliterans, emphysema, pulmonary edema, eosinophilic pneumonia, ABPA, Churg-Strauss syndrome, benign, malignant tumors, co-morbidities, cigarette smoking, anti-inflammatory therapy, synergistically
Abstract: Severe asthma is a complex and heterogeneous phenotype characterized by persistent symptoms and poor control. While some patients respond to high doses of inhaled corticosteroids in combination with long-acting beta-agonists, a significant subset require oral corticosteroids to achieve symptom control. This issue has led to the development of alternative therapeutic strategies for severe asthma. This article provides an overview of current therapeutic strategies and suggests how they can be best applied to the treatment of severe asthma. The article then reviews alternative therapeutic strategies including macrolide antibiotics, biologic agents, modulators of signal transduction pathways and bronchial thermoplasty. The challenge remains to determine the appropriate phenotype for each therapeutic strategy in view of the heterogeneity of severe asthma.
Export Options
About this article
Cite this article as:
Oliveinstein Ron, Al Jahdali Hamdan, Alkhamis Nouf, Halwani Rabih, Al-Muhsen Saleh and Hamid Qutayba, Challenges in the Management of Severe Asthma: Role of Current and Future Therapies, Current Pharmaceutical Design 2011; 17 (7) . https://dx.doi.org/10.2174/138161211795428993
DOI https://dx.doi.org/10.2174/138161211795428993 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
How to Measure Exercise Performance
Current Respiratory Medicine Reviews An Overview of Recent Patents on Nanosuspension
Recent Patents on Drug Delivery & Formulation Latest Development in Drug Discovery on G Protein-coupled Receptors
Current Protein & Peptide Science Innovative Targets For Asthma And COPD: Exploring The Existing And Screening The New!!
Infectious Disorders - Drug Targets CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer
Current Drug Targets Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Cationic Surfactants and Lipids as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Fractions of <i>Boswellia Serrata</i> Suppress LTA<sub>4</sub>, LTC<sub>4</sub>, Cyclooxygenase-2 Activities and mRNA in HL-60 Cells and Reduce Lung Inflammation in BALB/c Mice
Current Drug Discovery Technologies Allergy and Inflammation: An Immunological and Therapeutic Approach
Recent Patents on Inflammation & Allergy Drug Discovery TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease
Current Drug Targets Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Acute Effects of Passive Smoking on Asthma in Childhood
Inflammation & Allergy - Drug Targets (Discontinued) Regulation of the Endoplasmic Reticulum Ca2+-Store in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role of Neutrophils and TH17 Cells in the Immunopathology of Severe Asthmax
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anti-oxidant and Anticancerous Effect of <i>Fomitopsis officinalis</i> (Vill. ex Fr. Bond. et Sing) Mushroom on Hepatocellular Carcinoma Cells <i>In Vitro</i> through NF-kB Pathway
Anti-Cancer Agents in Medicinal Chemistry The Proteasome in Health and Disease
Current Pharmaceutical Design The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Ligand and Structure Based Models for the Identification of Beta 2 Adrenergic Receptor Antagonists
Current Computer-Aided Drug Design Should Serology be Abolished in Favor of PCR for the Diagnosis of Mycoplasma pneumoniae Infections?
Current Pediatric Reviews